Less increase of copeptin and MR-proADM due to intervention with selenium and coenzyme Q10 combined: Results from a 4-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens., 2015, Biofactors, (41), 6, 443-452 Therefore 437 elderly individuals were included and given intervention for 4 years.
repeated measures of variance. Cardiovascular mortality was evaluated using a 10-50 year-period of follow-up, and presented in Kaplan-Meier plots. 51 A significant increase in copeptin level could be seen in the placebo group during the 52 intervention period (from 9.4 pmol/L to 15.3 pmol/L), compared to the active 53 treatment group. The difference between the groups was confirmed in the repeated 54 measurement of variance analyses (P=0.031) with less copeptin increase in the 55 active treatment group. Furthermore, active treatment appeared to protect against 56 cardiovascular death both in those with high and with low copeptin levels at inclusion.
57
Less increase of MR-proADM could also be seen during the intervention in the active 58 treatment group compared to controls (P=0.026). Both in those having an MR-59 proADM level above or below median level, significantly less cardiovascular mortality 60 could be seen in the active treatment group (P=0.0001, and P=0.04 respectively).
61
In conclusion supplementation with selenium and coenzyme Q10 during four years 62 resulted in less concentration of both copeptin and MR-proADM. A cardioprotective 63 effect of the supplementation was registered, irrespective of the initial levels of these 64 biomarkers, and this protection was recognized also after 10 years of observation.
We have previously reported on the effect of dietary supplementation of selenium Selenium, one of the trace elements, is essential for all living cells [7, 8] . It is mostly 88 found as selenoproteins in the body, including glutathione peroxidases, thioredoxin 89 reductase and selenoprotein P, which protects against oxidative stress [9] . 90 However, selenium is also important in the inflammatory response in different 91 disease states [10] , and increased vascular oxidative stress and endothelial 92 dysfunction have been reported to characterize patients with coronary heart disease 93 [11, 12] . An important interrelationship between selenium and coenzyme Q10 
131
The present study report that the concentrations of copeptin and MR-proADM 132 decreases or stabilizes as a result of the intervention. Secondly, the project could 133 present a reduced cardiovascular mortality in the active intervention group,
134
irrespective of the levels of the two biomarkers also after a 10 years of follow-up. 
METHODS

138
Study population
139
This is a secondary analysis of a prospective randomized double-blind placebo- one of food supplement commodities that are commercially available).
155
All mortality was registered, and followed until 10 years after the end of the study. 
Blood samples
158
Blood samples were collected while the participants were resting in a supine position.
159
Pre-chilled, EDTA vials were used. The vials were centrifuged at 3000g, +4 o C, and
160
were then frozen at -70ºC. No sample was thawed more than once. 
RESULTS
202
The baseline characteristics of the study population are presented in Table 1 , and a
203
CONSORT flow chart of the study is presented in Fig.1 . The follow-up period in the or ischemic heart disease between the two groups.
215
At inclusion, the concentrations of NT-proBNP were almost equal in the two groups Table 2 . Thus, a significant increase in copeptin concentration occurred in the placebo group 232 between the start and end of the study (P=0.001).
233
To further explore the possible treatment effect a repeated measures of variance was 234 performed. This evaluation showed a significant treatment effect on the copeptin level 235 (F=4.85; P=0.009), indicating that a significant difference between active intervention 236 and placebo existed. Evaluation of the interaction revealed a significant interaction 237 (F= 3.54; P=0.03) indicating that the obtained treatment effect was not based on 238 differences in the copeptin levels of the two groups at the start, but to a significantly 239 reduced level of copeptin due to the intervention (Fig. 2) . (Table 3) . Thus, a significant treatment effect was seen on the MR-proADM level (Fig. 4) . with a plasma concentration of MR-proADM above the median is presented in Figure   274 5a. It was found that in those with an MR-proADM concentration at the study start (Fig. 5b) .
280
The overall risk of cardiovascular mortality when applying a 10 year follow-up period In the actively supplemented group the circulating levels of these two biomarkers did With regard to MR-proADM, a similar difference appeared between the 328 supplemented and the control groups as described above for copeptin. 
367
The two biomarkers monitored in this study, copeptin and MR-proADM, may reflect 
CONCLUSION
377
The concentration of the biomarkers copeptin and MR-proADM reflects the intensity 378 of oxidative stress in the body, although they may be influenced by other processes. 
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